American Century Companies Inc. Has $300,000 Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

American Century Companies Inc. lowered its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 14.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 8,541 shares of the company’s stock after selling 1,392 shares during the quarter. American Century Companies Inc.’s holdings in IDEAYA Biosciences were worth $300,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Franklin Resources Inc. boosted its holdings in shares of IDEAYA Biosciences by 4.9% in the 4th quarter. Franklin Resources Inc. now owns 27,237 shares of the company’s stock valued at $969,000 after purchasing an additional 1,260 shares in the last quarter. Capital Research Global Investors boosted its holdings in shares of IDEAYA Biosciences by 43.6% in the 4th quarter. Capital Research Global Investors now owns 1,976,870 shares of the company’s stock valued at $70,337,000 after purchasing an additional 600,000 shares in the last quarter. Superstring Capital Management LP acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $8,941,000. First Light Asset Management LLC acquired a new stake in shares of IDEAYA Biosciences in the 4th quarter valued at $12,299,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of IDEAYA Biosciences by 17.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,566,278 shares of the company’s stock valued at $126,889,000 after purchasing an additional 535,909 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 2.5 %

IDYA stock opened at $29.97 on Friday. The stock has a 50-day moving average price of $36.73 and a 200-day moving average price of $38.78. IDEAYA Biosciences, Inc. has a 1-year low of $23.41 and a 1-year high of $47.74. The firm has a market cap of $2.27 billion, a PE ratio of -14.91 and a beta of 0.84.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same period in the prior year, the business earned ($0.50) earnings per share. On average, analysts forecast that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Lifesci Capital upgraded IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. Oppenheimer dropped their price target on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Stifel Nicolaus increased their price target on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Wedbush dropped their price target on IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a research note on Tuesday, September 24th. Finally, BTIG Research increased their price target on IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Twelve research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of “Buy” and an average target price of $56.00.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.